These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis. Khan SU; Rahman H; Okunrintemi V; Riaz H; Khan MS; Sattur S; Kaluski E; Lincoff AM; Martin SS; Blaha MJ J Am Heart Assoc; 2019 Apr; 8(7):e011581. PubMed ID: 30898075 [TBL] [Abstract][Full Text] [Related]
5. Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant Cholesterol. Masson W; Lobo M; Molinero G; Siniawski D Arq Bras Cardiol; 2017 Jun; 108(6):526-532. PubMed ID: 28699976 [TBL] [Abstract][Full Text] [Related]
6. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949 [TBL] [Abstract][Full Text] [Related]
7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
8. Effect of long-term intensive cholesterol control on the plaque progression in elderly based on CTA cohort study. Sun T; Wang Y; Wang X; Hu W; Li A; Li S; Xu X; Cao R; Fan L; Cao F Eur Radiol; 2022 Jul; 32(7):4374-4383. PubMed ID: 35226154 [TBL] [Abstract][Full Text] [Related]
10. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695 [TBL] [Abstract][Full Text] [Related]
11. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Varbo A; Benn M; Nordestgaard BG Pharmacol Ther; 2014 Mar; 141(3):358-67. PubMed ID: 24287311 [TBL] [Abstract][Full Text] [Related]
12. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL; J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286 [TBL] [Abstract][Full Text] [Related]
13. Perspectives on low-density lipoprotein cholesterol goal achievement. Catapano AL Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials. Patti G; Spinoni EG; Grisafi L; Mehran R; Mennuni M Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):138-147. PubMed ID: 36102667 [TBL] [Abstract][Full Text] [Related]